Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 0.47 |
| ▸ | FDPS | P14324 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 8/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.38 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7944792 | 0.82 | CA1 (0.50) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL15386601 | 0.78 | CA1 (0.52) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL3003475 | 0.77 | CA1 (0.50) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL6674983 | 0.77 | CA1 (0.50) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL6681186 | 0.77 | CA1 (0.50) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL15386600 | 0.77 | CA1 (0.45) | CA1FDPSCA2MAPK1ACE2 | |
| SCHEMBL7546267 | 0.77 | — | — | |
| SCHEMBL10037941 | 0.77 | — | — | |
| SCHEMBL7916216 | 0.77 | — | — | |
| SCHEMBL859004 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048461-A1 | Regulators of Bacterial Signalling Pathways | BIOSIGNAL LIMITED (AU) | 2009-02-19 | — | — | US | disclosed |
| EP-0768294-B1 | Process for preparing 2,4,4,7-tetramethyl-oct-6-en-3-on and its use as perfume | HAARMANN & REIMER GMBH (DE) | 2001-09-12 | — | — | EP | disclosed |
| US-6252120-B1 | ALKENYLATION OF DIISOPROPYL KETONE WITH 1-CHLORO-3-METHYL-2-BUTENE IN AN AQUEOUS PHASE CATALYZED BY A PHASE TRANSFER CATALYST | HAARMANN & REIMER GMBH (DE) | 2001-06-26 | — | — | US | disclosed |
| EP-0768294-A1 | Process for preparing 2,4,4,7-tetramethyl-oct-6-en-3-on and its use as perfume | HAARMANN & REIMER GMBH (DE) | 1997-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048461-A1 | Regulators of Bacterial Signalling Pathways | MRPL21, FNTB, ATF1 | CA1 4884/4885FDPS 4/4885CA2 4363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.